TAT-NSF222 Fusion Peptide

TAT-NSF222 is a cell-permeable fusion peptide composed of the HIV TAT(47-57) protein-transduction domain, a Gly3 linker and an NSF-derived segment adjacent to the Walker A region of the NSF D1 ATPase domain. The peptide was developed as an experimental inhibitor of N-ethylmaleimide-sensitive factor (NSF). Published work shows that TAT-NSF fusion peptides can enter endothelial cells, inhibit NSF ATPase/disassembly functions and reduce regulated exocytosis.

• NSF ATPase research
• SNARE-complex disassembly studies
• regulated endothelial exocytosis
• cell-penetrating inhibitory peptide research

Reported inhibition is specific to the experimental systems and concentrations studied. This peptide should be paired with an appropriate scrambled control, such as TAT-NSF222scr, when attributing effects to the NSF-derived sequence.

1. A Novel Class of Fusion Polypeptides Inhibits Exocytosis
2. P2X4-Receptor-Mediated Synthesis and Release of Brain-Derived Neurotrophic Factor in Microglia Is Dependent on Calcium and p38-Mitogen-Activated Protein Kinase Activation